
PBM
Healthcare · Biotechnology · $12.0M market cap
$3.15+0.06 (+1.8%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 20, 2025 | Time not confirmed | — | -0.51 | — |
| Jun 25, 2025 | Time not confirmed | — | -99.97 | — |
| Jan 23, 2025 | Time not confirmed | — | 4.06 | — |
| Mar 23, 2023 | Time not confirmed | — | 0.05 | — |
| Nov 14, 2022 | Time not confirmed | — | 0.03 | — |
| Aug 15, 2022 | Time not confirmed | — | 0.07 | — |
| Apr 1, 2022 | Time not confirmed | — | 0.25 | — |
| Oct 21, 2021 | Time not confirmed | — | 0.25 | — |
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a…